Study of a Birth Dose of GlaxoSmithKline Biologicals' 251154 Vaccine

Inclusion Criteria: * Subjects who the investigator believes that their parent(s)/LAR(s) can and will comply with the requirements of the protocol. * Written informed consent obtained from the parent(s)/LAR(s) of the subject. * A male or female infant between, and including, 2 and 5 days of age at the time of randomisation. * Subjects who are born after an uncomplicated gestation period of 36 to 42 weeks inclusive. * Subjects born to a mother seronegative for hepatitis B surface antigen. * Subjects with a birth weight \>= 2.5 kg. * Subjects with a 5-minute Apgar score \>= 7. * Healthy subjects as established by medical history and clinical examination Exclusion Criteria: * Use of any investigational or non-registered product other than the study vaccines since birth, or planned use during the study period. * Born to a mother known or suspected to be seropositive for HIV. * Family history of congenital or hereditary immunodeficiency. * Children in care.. * Neonatal jaundice requiring systemic treatment. * Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period. * Administration of any vaccine since birth or planned administration during the study period with the exception of inactivated influenza vaccines. * Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product. * History of seizures or progressive neurological disease. * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines. * Major congenital defects or serious chronic illness, including perinatal brain damage. The following condition is temporary or self-limiting, and a subject may be vaccinated once the condition has resolved if no other exclusion criteria is met: • Current febrile illness or temperature \>= 38.5°C on oral or axillary setting, or \>= 39.0°C on rectal setting, or other moderate to severe illness within 24 hours of study vaccine administration.